Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover study of inhaled AZD9164 versus tiotropium in COPD
2009-010864-40Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd-9164 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: FEV1 average effect over 24 hours (Eav), FEV1 maximum effect (Emax) and 1 more. Started Apr 2009; status: completed.
02
Drugs
azd-9164
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-010864-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010864-40.